melanotan-2 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-14. Numbers and descriptions here follow the published literature rather than marketing material.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
spatially-restricted gene expression The expression of one or more genes only within a specific anatomical region or tissue, often in response to a paracrine signal. The boundary between the jurisdictions of two spatially restricted genes may generate a sharp phenotypic gradient there, as with striping patterns.
Given n and m, one can reverse this theoretical operation by drawing the vector w on the graphene lattice, cutting a strip of the latter along lines perpendicular to w through its endpoints A1 and A2, and rolling the strip into a cylinder so as to bring those two points together. If this construction is applied to a pair (k,0), the result is a zigzag nanotube, with closed zigzag paths of 2k atoms. If it is applied to a pair (k,k), one obtains an armchair tube, with closed armchair paths of 4k atoms.
=== Use in molecular biology === Because RIP is so efficient at detecting and mutating repeats, biologists working on Neurospora crassa have used it as a tool for mutagenesis. A second copy of a single-copy gene is first transformed into the genome. The fungus must then mate and go through its sexual cycle to activate the RIP machinery. Many different mutations within the duplicated gene are obtained from even a single fertilization event so that inactivated alleles, usually due to nonsense mutations, as well as alleles containing missense mutations can be obtained.
where K is an optical constant and c is the solution concentration. Using a differential refractometer (DRI) to measure the concentration of the solution, an absolute molar mass can be calculated. More accurate measurements can be made by using a low-angle static light scattering (LALS) detector, which operates at a very low angle and therefore do not require angular effects to be corrected. However, these detectors are very sensitive to particles, which leads to noisy data and are therefore rarely used. LALS detectors have largely been replaced by MALS detectors, which measures scattered light at multiple angles simultaneously and extrapolates the data to θ = 0° to obtain a weight-average molar mass. The coupling of SEC with MALS detection have become the benchmark for the determination of absolute molecular mass, particularly averages masses and distributions. Viscometry detectors, although less common, also function as detectors of absolute molar mass. Unlike light scattering photometers which do not use a calibration curve, viscometers apply a universal calibration curve where the logarithm of intrinsic viscosity multiplied by molar mass can be plotted against the retention volume from SEC. This method is effective for calculating the absolute molar mass of a wide variety of polymers, including rod-like polymers and dendrimers. Several other methods of analysis are used to determine the absolute molar mass.
3 ArOH + FeCl3 → Fe(OAr)3 + 3 HCl (Ar = aryl) Among the halide and pseudohalide complexes, fluoro complexes of iron(III) are the most stable, with the colorless [FeF5(H2O)]2− being the most stable in aqueous solution. Chloro complexes are less stable and favor tetrahedral coordination as in FeCl4−; FeBr4− and FeI4− are reduced easily to iron(II). Thiocyanate is a common test for the presence of iron(III) as it forms the blood-red [FeSCN(H2O)5]2+. Like manganese(II), most iron(III) complexes are high-spin, the exceptions being those with ligands that are high in the spectrochemical series such as cyanide. An example of a low-spin iron(III) complex is [Fe(CN)6]3−. Iron shows a great variety of electronic spin states, including every possible spin quantum number value for a d-block element from 0 (diamagnetic) to 5⁄2 (5 unpaired electrons). This value is always half the number of unpaired electrons. Complexes with zero to two unpaired electrons are considered low-spin and those with four or five are considered high-spin. Iron(II) complexes are less stable than iron(III) complexes but the preference for O-donor ligands is less marked, so that for example [Fe(NH3)6]2+ is known while [Fe(NH3)6]3+ is not. They have a tendency to be oxidized to iron(III) but this can be moderated by low pH and the specific ligands used.
Sources: en.wikipedia.org
If arterial/venous is not specified for an acid–base or blood gas value, then it generally refers to arterial, and not venous which otherwise is standard for other blood tests. Acid–base and blood gases are among the few blood constituents that exhibit substantial difference between arterial and venous values. Still, pH, bicarbonate and base excess show a high level of inter-method reliability between arterial and venous tests, so arterial and venous values are roughly equivalent for these.
The large POMC precursor is the source of numerous biologically active peptides, which are produced through sequential enzymatic cleavage. These include: N-Terminal Peptide of Proopiomelanocortin (NPP, or pro-γ-MSH) α-Melanotropin (α-Melanocyte-Stimulating Hormone, or α-MSH) β-Melanotropin (β-MSH) γ-Melanotropin (γ-MSH) 𝛿-Melanocyte-Stimulating Hormone (𝛿-MSH), found in sharks ε-Melanocyte-Stimulating Hormone (ε-MSH), present in some teleost fish Corticotropin (Adrenocorticotropic Hormone, or ACTH) Corticotropin-like Intermediate Peptide (CLIP) β-Lipotropin (β-LPH) Gamma Lipotropin (γ-LPH) β-Endorphin [Met]Enkephalin Although the first five amino acids of β-Endorphin are identical to [Met]enkephalin, β-Endorphin is not generally believed to be a precursor of [Met]enkephalin. Instead, [Met]enkephalin is produced independently from its own precursor, proenkephalin A. The production of β-MSH occurs in humans, but not in mice or rats, due to the absence of the necessary cleavage site in the rodent POMC sequence.
== Personal life, illness and death == On 7 July 1967, Olofsson became engaged to Madiorie Britmer in prison. He married Marijke Demuynck from Belgium in 1976; they occasionally lived in a large house in the Belgian countryside. The marriage with Marijke ended in 1999. He was the father of six children: the youngest son with his fiancée, three older sons with Marijke and two daughters from before his marriage. Olofsson died in Arvika, Sweden, on 24 June 2025, aged 78, following a long period of ill health.
== Work in wound healing == Bale was part of the original team that established a unique wound healing service in the Wound Healing Research Unit, based at the University of Wales College of Medicine. She has written a range of books and articles on wound care. She is a founder member of the Wound Care Society (1985); the European Wound Management Association; (1991); the Journal of Wound Care (1992); the European Pressure Ulcer Advisory Panel (1996).
Sources: en.wikipedia.org
Unlike the fast integration and intermarriages of creoles with Africans and Hispanics in Belize City, the creoles in the Belize river valley area had a lighter complexion and more visible European traits. The Belizean Creole along with Africans and Garifuna make up the Afro-Belizean population; about 30% of the population. The Creoles have had a great impact in Belizean history and politics. They were active and part of the Battle of St George's Caye, Part of the British West Indies Battalion in world war one and world war two, and the Negro movement for equal rights. They were one of the first group of people to advocate for and get a higher education in Jamaica and the UK in which after returning to Belize, the educated scholars rallied and started the movement for adult suffrage, self-government and independence. All of the important historical events started in Belize City and most of the first people involved were of creole descent which were the upper and middle class of Belize at the time. Well known Creole Belizeans were Samuel Haynes, Philip Goldson, Dean Barrow, Dame Minita Gordon, Cleopatra White, Cordel Hyde and Patrick Faber among others. The Creole were the biggest ethnic group in Belize until the 1980s due to mass migration of Afro Belizeans to the United States, United Kingdom and West Indies from the 1960s to 1970s and the mass immigration of Central American refugees to Belize. Due to the Central American War, and political instability, the country's demographics changed forever.
The West China School/Hospital of Stomatology (Chinese: 四川大学华西口腔医学院 华西口腔医院) is a public tertiary dental school and hospital in Chengdu, Sichuan, China. Owned and operated by the West China Medical Center of Sichuan University, it specializes in dentistry and oral and maxillofacial medicine. The institution traces its origins to the Renji Dental Clinic established in Chengdu in 1907 by Canadian dentist Ashley Woodward Lindsay. The clinic was expanded into a dental hospital in 1912, and in 1917, the dental school of West China Union University was established. Modern histories of dental education identify the West China Union University dental program as the earliest institution of higher dental education in China. The institution is a Grade-III, Class-A specialist hospital and hosts national clinical, research and training programs in oral medicine. In 2020, the National Health Commission entrusted the institution to serve as one of the three National Centers for Stomatology in the country.
=== CHIP, Medicaid, and Medicare Coverage === In April 2025, the Trump Administration declined to finalize a Biden Administration proposal that would have required Medicare, Medicaid, and the Children's Health Insurance Program (CHIP) to broadly cover GLP-1 drugs for weight loss. In November 2025, the Trump Administration announced TrumpRx to lower the price of GLP-1 drugs to $245 per month for people covered by Medicare. Coverage for people with obesity and at least one comorbidity (elevated LDL-cholesterol, high blood pressure and/or MASLD) may be implemented as early as April 2026. The cost will be significantly higher because most insurance companies do not cover it in their formulary. Before this change, most people covered by Medicaid and CHIP paid $3 a month, the same as for brand-name medications. Starting in July 2026, eligible Medicare beneficiaries will gain access to certain weight-loss medications for $50 a month through a temporary initiative called the Medicare GLP-1 Bridge program. This pilot is designed to create a more affordable pathway for people who need these treatments while broader, long-term coverage options are being finalized.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.